WaveMan
WaveMan · Company
RCEL · Avita Medical, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RCEL AVITA Medical (RCEL) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001762303
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
43
13F, latest reported quarter

What the filings say about RCEL

Insiders, 180 days
+$213.5K net bought
2 buyers

AVITA Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, AVITA Medical, Inc. insiders bought a net $213.5K of stock across 53 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
O'Toole David D
CFO
BUY
2026-08-24 SECtraded 2026-06-12
2,000
$7.9K
+44.6%
Context
  • 30 earlier Form 4 trades (code P or S) here by this insider (30 buys), the last on May 20, 2026.
  • -3.4% median (+10.9% mean) 90-day return after 20 previous buys.
  • The trade is 1.3% of the 152,927 shares held after it.
  • 1 other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO O'Toole David D bought about $7.9K of RCEL on Jun 12, 2026; 1 other insider bought within 30 days and 43 funds added in the latest 13F quarter.
Woody Joseph Fralin
Director
BUY
2026-06-10 SECtraded 2026-06-09
5,200
$20.8K
+282.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 3, 2026.
  • +141.1% median (+137.9% mean) 90-day return after 3 previous buys.
  • The trade is 4.8% of the 107,961 shares held after it.
  • 1 other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Woody Joseph Fralin bought about $20.8K of RCEL on Jun 9, 2026; 1 other insider bought within 30 days and 43 funds added in the latest 13F quarter.
Woody Joseph Fralin
Director
BUY
2026-06-09 SEC
5,000
$20.9K
+268.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 3, 2026.
  • +141.1% median (+137.9% mean) 90-day return after 3 previous buys.
  • The trade is 4.9% of the 102,761 shares held after it.
  • 1 other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Woody Joseph Fralin bought about $20.9K of RCEL on Jun 9, 2026; 1 other insider bought within 30 days and 43 funds added in the latest 13F quarter.
Woody Joseph Fralin
Director
BUY
2026-06-09 SEC
5,000
$21.0K
+268.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 3, 2026.
  • +141.1% median (+137.9% mean) 90-day return after 3 previous buys.
  • The trade is 5.1% of the 97,761 shares held after it.
  • 1 other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Woody Joseph Fralin bought about $21.0K of RCEL on Jun 9, 2026; 1 other insider bought within 30 days and 43 funds added in the latest 13F quarter.
Woody Joseph Fralin
Director
BUY
2026-06-05 SECtraded 2026-06-03
5,000
$20.4K
+264.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jun 2, 2026.
  • +135.8% median (+135.8% mean) 90-day return after 2 previous buys.
  • The trade is 5.4% of the 92,761 shares held after it.
  • 1 other insider bought within 30 days.
  • 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Woody Joseph Fralin bought about $20.4K of RCEL on Jun 3, 2026; 1 other insider bought within 30 days and 43 funds added in the latest 13F quarter.
53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 48 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$213.5K over 180 days
more than 79% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
43 funds bought in last quarter
below 62% of Medical Devices
Revenue
+10.9% year over year
more than 52% of Medical Devices
Margin
-68.5% net margin
below 74% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.3% of the float short (float per yahoo 2026-10-27) · 7.6 days to cover · settled 2026-10-15
more than 84% of Medical Devices
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 12 in the prior 90
Why it matters
The absence is the signal: 12 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch RCEL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+277.6%12M
-19%+83%+184%+286%2025-102025-122026-022026-042026-062026-082026-10 2026-06-01 · Woody Joseph Fralin bought $21.7K2026-06-01 · Woody Joseph Fralin bought $21.3K2026-06-02 · Woody Joseph Fralin bought $21.1K2026-06-09 · Woody Joseph Fralin bought $21.0K2026-06-02 · Woody Joseph Fralin bought $20.9K2026-06-09 · Woody Joseph Fralin bought $20.9K2026-06-09 · Woody Joseph Fralin bought $20.8K2026-06-03 · Woody Joseph Fralin bought $20.5K2026-06-03 · Woody Joseph Fralin bought $20.4K2026-02-19 · O'Toole David D bought $12.5K2026-03-11 · O'Toole David D bought $8.6K2026-05-20 · O'Toole David D bought $8.5K2026-05-19 · O'Toole David D bought $8.5K2026-06-12 · O'Toole David D bought $7.9K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RCEL: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,333,914 sh
$5.5M
BlackRock, Inc.
564,952 sh
$2.3M
GEODE CAPITAL MANAGEMENT, LLC
339,822 sh
$1.4M
MARSHALL WACE, LLP
338,387 sh
$1.4M
AQR CAPITAL MANAGEMENT LLC
321,013 sh
$1.3M

Congress trades in RCEL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RCEL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RCEL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$432.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$29.1K position · as of 2026-06-30
0.0%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$80.0K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$55.5K position · as of 2026-05-31
0.0%
Goldman Sachs Absolute Return Tracker Fund
$174.4K position · as of 2026-06-30
0.0%
Morgan Stanley Pathway Small-Mid Cap Equity ETF
$15.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
11
Not applicable
0 active
What changed recently
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When P
2026-09-24 · Active Not Recruiting → Completed
Not applicable
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for
2026-09-24 · Active Not Recruiting → Completed
Not applicable
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $213.5K bought by insiders over 180 days, 43 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

RCEL financials

Revenue growth
+10.9%
XBRL, annual
Net margin
-68.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$75.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-57.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$24.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.52x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-81.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$507.0M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-5.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$71.6M$64.3M$50.1M$34.4M
Gross profit$58.8M$55.2M$42.4M$28.4M
Operating income-$42.5M-$56.6M-$42.7M-$27.5M
Net income-$48.6M-$61.8M-$35.4M-$26.7M
EPS (diluted)-1.74-2.39-1.401.07
Operating cash flow-$31.2M-$48.9M-$38.0M-$19.1M
Cash$10.2M$14.1M$22.1M$18.2M
Long-term debt$0$42.2M$39.8Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

RCEL Stock Sonar score 5/7 axes

Find similar shapesCompare

RCEL ranks highest on insider conviction (76th percentile) and risk and compliance (51st), and lowest on institutional and government (24th), among Medical Devices peers.

HealthGrowthInsidersInstitutionsRisk
Financial health
44
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.52x · 44 pct, sector of 150
Growth
36
Inputs
  • Revenue growth, YoY+10.9% · 52 pct, sector of 219
  • Backlog growth, YoY-10.0% · 19 pct, sector of 37
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$214K · 78 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
24
Inputs
  • Funds adding, latest quarter43 · 38 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$45K · 10 pct, sector of 50
Risk and compliance
51
Inputs
  • Short interest, % of float+9.3% · 24 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+15.4% · 28 pct, sector of 198
2 not measured: Profitability, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RCEL filings, in plain words

Are AVITA Medical insiders buying or selling RCEL?

In the 180 days to 2026-10-28, AVITA Medical insiders were net buyers, a net $213.5K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, AVITA Medical insiders were net buyers of RCEL, a net $213.5K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies